Infliximab therapy inhibits inflammation-induced angiogenesis in the mucosa of patients with crohn's disease

American Journal of Gastroenterology

Volumn 106, Issue 4, 2011, Pages 762-770

  Rutella, Sergio ^a,b   Fiorino, Gionata ^c   Vetrano, Stefania ^c   Correale, Carmen ^c   Spinelli, Antonino ^c   Pagano, Nico ^c   Arena, Vincenzo ^a   Maggiano, Nicola ^a   Repici, Alessandro ^c   Malesci, Alberto ^c,d   Danese, Silvio ^c  

^a CATHOLIC UNIVERSITY   (Italy)

^b IRCCS SAN RAFFAELE PISANA   (Italy)

^c HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD31 ANTIGEN; INFLIXIMAB; KI 67 ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN A;

ADULT; ANGIOGENESIS; ARTICLE; BLOOD ANALYSIS; CELL MIGRATION; CLINICAL ARTICLE; CONTROLLED STUDY; CROHN DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROBLAST; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MICROVASCULATURE; MUCOSA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REMISSION;

ADULT; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; BLOOD VESSELS; CELL MOVEMENT; CROHN DISEASE; ENDOTHELIAL CELLS; FEMALE; FIBROBLASTS; HUMANS; INTESTINAL MUCOSA; KI-67 ANTIGEN; MALE; MICROCIRCULATION; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTOR A; YOUNG ADULT;

EID: 79953797881     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2011.48     Document Type: Article

References (30)

1. Danese S, Fiocchi C Etiopathogenesis ofInfammatory bowel diseases. World J Gastroenterol 2006;12:4807-12. (Pubitemid 44323204)
2. Hanauer SB. Te expanding role of biologic therapy for IBD. Nat Rev Gastroenterol Hepatol 2010;7:63-4.
3. Melmed GY, Targan SR. Future biologic targets for IBD: potentials and pitfalls. Nat Rev Gastroenterol Hepatol 2010;7:110-7.
4. Dignass A, Van Assche G, Lindsay JO et al Te second European evidence-based consensus on the diagnosis and management of Crohn's disease: current management. J Crohns Colitis 2010;4:28-62.
5. Kirman I, Whelan RL, Nielsen OH. Inf iximab: mechanism of action beyond TNF-α neutralization in Infammatory bowel disease. Eur J Gastroenterol Hepatol 2004;16:639-41. (Pubitemid 38901630)
6. Targan SR Hanauer SB, van Deventer SJ et al A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997;337:1029-35.
7. Rutgeerts P, Feagan BG, Lichtenstein GR et al Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004;126:402-13. (Pubitemid 38182297)
8. Mitoma H, Horiuchi T, Hatta N et al Infiximab induces potent antiInfammatory responses by outside-to-inside signals through transmembrane TNF-α. Gastroenterology 2005;128:376-92. (Pubitemid 40431090)
9. Meusch U, Rossol M, Baerwald C et al. Outside-to-inside signaling through transmembrane tumor necrosis factor reverses pathologic interleukin-1 β production and def cient apoptosis of rheumatoid arthritis monocytes. Arthritis Rheum 2009;60:2612-21.
10. Verri WA Jr, Souto FO, Vieira SM et al IL-33 induces neutrophil migration in rheumatoid arthritis and is a target of anti-TNF therapy Ann Rheum Dis 2010;69:1697-703.
11. Szekanecz Z, Besenyei T, Szentpetery A et al. Angiogenesis and vasculogenesis in rheumatoid arthritis. Curr Opin Rheumatol 2010; 22: 299-306.
12. Danese S, Sans M, de la Motte C et al Angiogenesis as a novel compo-nent of Infammatory bowel disease pathogenesis. Gastroenterology 2006;130:2060-73. (Pubitemid 43816964)
13. Danese S, Sans M, Spencer DM et al Angiogenesis blockade as a new therapeutic approach to experimental colitis. Gut 2007; 56: 855-62. (Pubitemid 46854204)
14. Scaldaferri F, Vetrano S, Sans M et al VEGF-A links angiogenesis and Infammation in Infammatory bowel disease pathogenesis. Gastroenterology 2009;136:585-95e5.
15. Winship DH, Summers RW, Singleton JW et al. National Cooperative Crohn's Disease Study: study design and conduct of the study Gastroenterology 1979;77:829-42. (Pubitemid 9257851)
16. Weidner N. Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors. Breast Cancer Res Treat 1995;36:169-80.
17. Vermeulen PB, Gasparini G, Fox SB et al Quantif cation of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation. Eur J Cancer 1996;32A:2474-84.
18. Danese S, Sans M, Scaldaferri F et al TNF-α blockade down-regulates the CD40/CD40L pathway in the mucosal microcirculation: a novel anti-Infammatory mechanism of Infiximab in Crohn's disease. J Immunol 2006;176:2617-24. (Pubitemid 43201714)
19. Arroyo AG, Iruela-Arispe ML. Extracellular matrix, Infammation, and the angiogenic response. Cardiovasc Res 2010;86:226-35.
20. Lugering N, Kucharzik T, GockelH et al Human intestinal epithelial cells down-regulate IL-8 expression in human intestinal microvascular endothelial cells; role of transforming growth factor-β 1 (TGF-β 1). Clin Exp Immunol 1998;114:377-84. (Pubitemid 28539596)
21. Ten Hove T, van Montfrans C, Peppelenbosch MP et al Infiximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut 2002. 50. 206-11. (Pubitemid 34087933)
22. Marini M, Bamias G, Rivera-Nieves J et al TNF-α neutralization ameliorates the severity of murine Crohn's-like ileitis by abrogation ofintestinal epithelial cell apoptosis. Proc Natl Acad Sci USA 2003;100: 8366-71. (Pubitemid 36842551)
23. Di Sabatino A, Ciccocioppo R Armellini E et al Serum bFGF and VEGF correlate respectively with bowel wall thickness and intramural blood f ow in Crohn's disease. Infamm Bowel Dis 2004;10:573-7. (Pubitemid 39276464)
24. Ferrante M, Pierik M, Henckaerts L et al Te role of vascular endothelial growth factor (VEGF) in Infammatory bowel disease. Infamm Bowel Dis 2006;12:870-8. (Pubitemid 44352714)
25. Olson JL, Courtney RJ, Mandava N. Intravitreal Infiximab and choroidal neovascularization in an animal model. Arch Ophthalmol 2007; 125: 1221-4. (Pubitemid 47403029)
26. Teodossiadis PG, Liarakos VS, Sfkakis PP et al Intravitreal administra-tion of the anti-tumor necrosis factor agent Infiximab for neovascular age-related macular degeneration. Am J Ophthalmol 2009; 147: 825-30, 830 e1.
27. Taha Y, Raab Y, Carlson M et al Steroids reduce local Infammatory media-tor secretion and mucosal permeability in collagenous colitis patients. World J Gastroenterol 2006;12:7012-8. (Pubitemid 44834893)
28. Binion DG, Otterson MF, Rafee P. Curcumin inhibits VEGF-mediated angiogenesis in human intestinal microvascular endothelial cells through COX-2 and MAPK inhibition. Gut 2008;57:1509-17.
29. Plamondon S Ng SC, Kamm MA. T alidomide in luminal and f stulizing Crohn's disease resistant to standard therapies. Aliment Pharmacol Ter 2007;25:557-67.
30. Carvalho AT, Souza H, Carneiro AJ et al Terapeutic and prophylactic thalidomide in TNBS-induced colitis: synergistic Effects on TNF-α, IL-12 and VEGF production. World J Gastroenterol 2007;13:2166-73. (Pubitemid 46851150)